Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will present at the Noble Financial Capital Markets’ 12th Annual Investor and Equity Conference on Wednesday, January 20, 2016 at 10:00 am Eastern Time. In addition, Dr. Tinkelenberg will be participating in a panel discussion entitled “The Brave New World of Cancer Immunotherapy” at 5:15 pm Eastern Time on Tuesday, January 19, 2016. The conference is being held at the Club Med in Sandpiper Bay, FL.

About Enumeral

Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.